The Global Peptic Ulcer Drugs Market focuses on pharmaceutical products used for the prevention and treatment of peptic ulcers, including gastric and duodenal ulcers. These therapies primarily work by reducing stomach acid, protecting the gastric lining, and eliminating Helicobacter pylori infection when it is a contributing factor. The market includes proton pump inhibitors (PPIs), potassium-competitive acid blockers (PCABs), H2-receptor antagonists, antacids, and other therapies.
The global Peptic Ulcer Drugs Market was valued at USD 5.71 billion in 2025 and is projected to reach USD 9.74 billion by 2035, expanding at a 5.48% CAGR during the forecast period.
Get Free Sample PDF Brochure:
https://www.marketresearchfuture.com/sample_request/2445
Market Drivers
Rising Prevalence of H. pylori Infection
The widespread prevalence of Helicobacter pylori infection remains a major factor supporting demand for peptic ulcer therapies. Increasing diagnosis and screening programs are helping identify patients who require eradication treatment and acid-suppression therapies.
Increasing Aging Population and NSAID Use
The growing global elderly population is contributing to demand for peptic ulcer drugs. Older adults are more likely to use nonsteroidal anti-inflammatory drugs (NSAIDs), which can increase the risk of gastric irritation and NSAID-associated ulcers.
Expansion of PCAB Therapies
Potassium-competitive acid blockers (PCABs) are emerging as an important therapeutic class. The MRFR report identifies PCABs as the fastest-growing drug-class segment, with a projected 9.83% CAGR through 2035, supported by expanding regulatory approvals and their use in H. pylori eradication regimens.
Growing Healthcare Awareness and Screening
Improved awareness of gastrointestinal disorders and expanded screening initiatives are supporting earlier diagnosis of peptic ulcers and H. pylori infection. Government-backed screening and eradication initiatives in several Asian markets are also contributing to market expansion.
Growth of Digital Pharmacies and E-Commerce
The increasing adoption of online pharmacies and digital prescription fulfillment is changing the distribution landscape for gastrointestinal medicines. Online pharmacies and e-commerce are projected to grow at an 11.50% CAGR through 2035, according to MRFR.
Market Challenges
Generic Price Competition
The mature proton pump inhibitor market faces significant price pressure from generic medicines. Widespread availability of generic omeprazole, pantoprazole, esomeprazole, and other PPIs can limit pricing growth for pharmaceutical manufacturers.
Antibiotic Resistance
Increasing antibiotic resistance among H. pylori strains can reduce the effectiveness of conventional eradication regimens. Resistance to antibiotics such as clarithromycin can require alternative or more complex treatment combinations.
Regulatory Concerns Regarding Long-Term Acid Suppression
Ongoing regulatory and clinical attention surrounding prolonged acid-suppression therapy may influence prescribing patterns. Healthcare providers increasingly evaluate the necessity and duration of long-term PPI treatment.
Pricing and Reimbursement Challenges
Price controls, generic competition, and differences in reimbursement policies can restrict the adoption of newer and more expensive therapies, particularly in price-sensitive emerging markets.
Limited Access to Advanced Gastrointestinal Care
In developing regions, limited access to specialist gastroenterology services, diagnostic testing, and modern pharmaceutical therapies can restrict treatment availability and market expansion.
Browse In-depth Market Research Report on Global Peptic Ulcer Drugs Market:
https://www.marketresearchfuture.com/reports/peptic-ulcer-drugs-market-2445
Market Segmentation
By Drug Class:
Proton Pump Inhibitors (PPIs): These include widely used acid-suppression medicines such as omeprazole, esomeprazole, and pantoprazole. PPIs represented the dominant drug-class segment, accounting for approximately 54.7% of global revenue in 2024.
Potassium-Competitive Acid Blockers (PCABs): PCABs provide a newer approach to acid suppression and are gaining adoption in H. pylori eradication and other gastrointestinal indications.
H2-Receptor Antagonists: These medicines reduce gastric acid production and continue to have applications in prescription and over-the-counter gastrointestinal treatment.
Antacids and Mucosal Protective Agents: These products provide symptomatic relief and protection of the gastrointestinal lining and remain important because of their accessibility and relatively low cost.
By Disease Indication:
Gastric Ulcer: Gastric ulcers represented the largest indication, accounting for approximately 43.0% of the market in 2024.
Duodenal Ulcer: Duodenal ulcers are commonly associated with H. pylori infection and continue to represent an important treatment segment.
Stress-Related Mucosal Damage: This segment is expanding alongside increasing critical-care admissions and broader use of ulcer-prophylaxis protocols.
NSAID-Induced Ulcer: Increasing NSAID utilization, particularly among aging populations and patients with chronic pain conditions, contributes to demand for preventive and therapeutic acid-suppression medicines.
By Distribution Channel:
Hospital Pharmacies: Hospital pharmacies represented the leading distribution channel, contributing approximately 46.8% of revenue in 2024.
Retail and Drug Stores: Retail pharmacies remain an important channel for prescription refills and over-the-counter gastrointestinal products.
Online Pharmacies and E-Commerce: Digital pharmacies are experiencing rapid expansion due to telemedicine adoption, home delivery, and convenient prescription fulfillment.
By Region:
North America: The region accounted for approximately 32.3% of the global market in 2024, supported by high healthcare expenditure, established pharmaceutical infrastructure, and widespread use of acid-suppression therapies.
Europe: Europe represented approximately 27.1% of the market in 2024, supported by strong generic penetration, established healthcare systems, and regulatory frameworks governing gastrointestinal therapies.
Asia-Pacific: Asia-Pacific is the fastest-growing regional market, with a projected 5.58% CAGR, supported by H. pylori screening initiatives, expanding healthcare access, and increasing adoption of newer therapies.
South America: Growing healthcare coverage and access to generic gastrointestinal medicines are supporting market development.
Middle East & Africa: Improving healthcare infrastructure, pharmaceutical access, and public healthcare programs are creating opportunities for market expansion.
Regional Insights
North America
North America represents a major market for peptic ulcer drugs. The United States accounts for the largest portion of the regional market, supported by high healthcare expenditure, established prescription-drug infrastructure, and adoption of newer acid-suppression therapies.
Europe
European markets benefit from well-developed healthcare systems and extensive generic pharmaceutical availability. Germany, the United Kingdom, France, Italy, and other European countries represent important markets for peptic ulcer therapies.
Asia-Pacific
Asia-Pacific is expected to experience strong growth. China, Japan, South Korea, and India are important markets due to expanding healthcare access, H. pylori screening and eradication initiatives, increasing insurance coverage, and growing awareness of gastrointestinal diseases.
Rest of the World
Latin America, the Middle East, and Africa are expected to provide additional opportunities as healthcare infrastructure develops and access to gastrointestinal diagnosis and treatment improves.
Key Players
AstraZeneca
Takeda Pharmaceutical
Pfizer
Johnson & Johnson
Abbott Laboratories
Daiichi Sankyo
Eisai Co.
Viatris
Sun Pharmaceutical Industries
Lupin Limited
These companies participate across branded therapies, generic PPIs, PCAB products, gastrointestinal portfolios, and related pharmaceutical markets.
Future Outlook
The Global Peptic Ulcer Drugs Market is expected to expand steadily through 2035, driven by continued demand for acid-suppression therapies, increasing H. pylori diagnosis and treatment, aging demographics, and the development of newer therapeutic classes.
The expansion of PCAB therapies, digital pharmacy channels, precision treatment approaches, and microbiome-guided therapies is expected to influence the competitive landscape. At the same time, generic price erosion, antibiotic resistance, regulatory scrutiny, and reimbursement challenges will remain important considerations for market participants.
The market is projected to grow from USD 5.71 billion in 2025 to USD 9.74 billion by 2035, at a 5.48% CAGR.
Related Report:
Discover emerging opportunities with in-depth research reports:
Live Cell Encapsulation Market Share
Specialty Medical Chairs Market Trends
Medical Vacuum Systems Market Growth
Veterinary Dental Equipment Market Volume
About Market Research Future:
Market Research Future (MRFR) is a global market research company providing market intelligence and analysis across diverse industries. Its research covers products, services, technologies, applications, end users, market players, and global, regional, and country-level market segments.
